TPG Biotech

ADCendo ApS is a biotechnology company focused on developing innovative anti-cancer drugs through the use of antibody-drug conjugates (ADCs). The company targets novel receptors that are overexpressed in various cancer types, addressing significant unmet medical needs in the field of oncology. Its ADCs aim to provide targeted therapy for patients suffering from aggressive cancers such as soft-tissue sarcoma, osteosarcoma, glioblastoma multiforme, and triple-negative breast cancer, as well as other carcinomas including those of the breast, colon, pancreas, prostate, ovary, and kidney. Through its research and development efforts, ADCendo strives to create effective treatment options for patients facing challenging cancer diagnoses.

Carisma Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative immunotherapies for cancer and other serious diseases through its proprietary chimeric antigen receptor macrophage technology. The company focuses on engineering macrophages and monocytes, which are specialized white blood cells, to enhance their ability to infiltrate solid tumors and deliver potent cellular immunotherapy. By leveraging advanced cell engineering techniques, Carisma aims to provide effective treatments that enable patients with solid tumors to benefit from targeted and robust cancer therapies.

Carisma Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative immunotherapies for cancer and other serious diseases through its proprietary chimeric antigen receptor macrophage technology. The company focuses on engineering macrophages and monocytes, which are specialized white blood cells, to enhance their ability to infiltrate solid tumors and deliver potent cellular immunotherapy. By leveraging advanced cell engineering techniques, Carisma aims to provide effective treatments that enable patients with solid tumors to benefit from targeted and robust cancer therapies.

Carisma Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative immunotherapies for cancer and other serious diseases through its proprietary chimeric antigen receptor macrophage technology. The company focuses on engineering macrophages and monocytes, which are specialized white blood cells, to enhance their ability to infiltrate solid tumors and deliver potent cellular immunotherapy. By leveraging advanced cell engineering techniques, Carisma aims to provide effective treatments that enable patients with solid tumors to benefit from targeted and robust cancer therapies.

Azura Ophthalmics is a clinical-stage company focused on developing innovative treatments for Meibomian Gland Dysfunction (MGD), a primary cause of dry eye disease (DED). The company's portfolio includes a range of compounds designed to address the underlying causes of MGD and improve health outcomes for individuals suffering from ocular surface diseases, where effective treatment options are limited. Azura utilizes a novel drug delivery platform to enhance the efficacy of its therapies. The company is headquartered in Tel Aviv-Yafo, Israel, with operational presence in Australia and the United States, and is supported by a management team experienced in the development and commercialization of novel ocular treatments.

DNAnexus, Inc. is a provider of cloud-based genome informatics and data management tools aimed at enterprises engaged in genomic medicine. Founded in 2009 and headquartered in Mountain View, California, the company offers a platform that facilitates the analysis of raw sequencing data and integration with clinical and phenotypic data, promoting seamless collaboration among users. Key offerings include MOSAIC Microbiome, a platform for collaborative microbiome research; DNAnexus Apollo, which focuses on clinico-genomic data exploration; and DNAnexus Titan, a comprehensive data analysis solution. Additionally, DNAnexus Portals provide secure online workspaces for cross-disciplinary collaboration. The Clinico-Genomic Data Solution program addresses the need for disease-specific datasets by building networks with healthcare partners to enhance diagnosis and treatment pathways. DNAnexus serves a diverse client base, including biopharmaceutical companies, genome centers, and diagnostic test providers, and has established a strategic alliance with WuXi NextCODE Genomics. The company also maintains additional offices in San Francisco, London, and Prague.

Avalyn Pharma, Inc. is a biopharmaceutical company focused on developing therapies for idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company is advancing inhaled formulations of pirfenidone, specifically AP01, which aims to enhance drug delivery to the lungs while potentially reducing side effects associated with oral treatments. This innovative approach seeks to improve the care and outcomes for patients suffering from these conditions. Established in 2011, Avalyn Pharma operates from its headquarters in Seattle, Washington, and maintains an additional office in San Diego, California. The company was previously known as Genoa Pharmaceuticals, Inc. before rebranding in July 2017.

Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative treatments for migraine. The company's lead product candidate, STS101, is a drug-device combination that features a proprietary dry-powder formulation of dihydroergotamine mesylate. This product is designed for self-administration through a pre-filled, single-use nasal delivery device and is currently undergoing Phase III clinical trials. Founded in 2016 and based in South San Francisco, California, Satsuma aims to provide an effective therapeutic option for individuals suffering from acute migraine episodes.

Fusion Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company headquartered in Hamilton, Canada, specializing in the development of radiopharmaceuticals as precision medicines for challenging cancers. The company employs its proprietary Targeted Alpha Therapies platform and Fast-Clear linker technology to connect alpha particle-emitting isotopes to antibodies, enabling the selective delivery of therapeutic agents to tumors. Fusion's lead product candidate, FPI-1434, is currently undergoing Phase 1 clinical trials as a monotherapy for solid tumors expressing insulin-like growth factor 1 receptor. Additionally, the company is exploring the use of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors in preclinical studies to enhance anti-tumor activity. Fusion is also advancing another product candidate, FPI-1966, into clinical development for head and neck and bladder cancers that express fibroblast growth factor receptor. Founded in 2014 as a spinout of the Centre for Probe Development and Commercialization, Fusion aims to transform how cancers are treated through innovative radiochemistry techniques.

DNAnexus, Inc. is a provider of cloud-based genome informatics and data management tools aimed at enterprises engaged in genomic medicine. Founded in 2009 and headquartered in Mountain View, California, the company offers a platform that facilitates the analysis of raw sequencing data and integration with clinical and phenotypic data, promoting seamless collaboration among users. Key offerings include MOSAIC Microbiome, a platform for collaborative microbiome research; DNAnexus Apollo, which focuses on clinico-genomic data exploration; and DNAnexus Titan, a comprehensive data analysis solution. Additionally, DNAnexus Portals provide secure online workspaces for cross-disciplinary collaboration. The Clinico-Genomic Data Solution program addresses the need for disease-specific datasets by building networks with healthcare partners to enhance diagnosis and treatment pathways. DNAnexus serves a diverse client base, including biopharmaceutical companies, genome centers, and diagnostic test providers, and has established a strategic alliance with WuXi NextCODE Genomics. The company also maintains additional offices in San Francisco, London, and Prague.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, dedicated to developing and commercializing nalbuphine ER, an oral extended-release formulation. The company is focused on treating serious neurologically mediated conditions, specifically chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in individuals with Parkinson's disease. Trevi is currently conducting a Phase 2b/3 clinical trial, known as the PRISM trial, for nalbuphine ER, targeting severe pruritus associated with prurigo nodularis. The conditions being addressed share similar underlying mechanisms that involve opioid receptors in both the central and peripheral nervous systems. Founded in 2011, Trevi Therapeutics aims to provide innovative treatment options for patients suffering from these challenging health issues.

Carisma Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative immunotherapies for cancer and other serious diseases through its proprietary chimeric antigen receptor macrophage technology. The company focuses on engineering macrophages and monocytes, which are specialized white blood cells, to enhance their ability to infiltrate solid tumors and deliver potent cellular immunotherapy. By leveraging advanced cell engineering techniques, Carisma aims to provide effective treatments that enable patients with solid tumors to benefit from targeted and robust cancer therapies.

Unchained Labs is a life sciences tools company based in Pleasanton, California, specializing in solutions for biologics and gene therapy researchers. Established in 2014, it develops a range of products designed to enhance the efficiency and effectiveness of research in protein stability and formulation. Key offerings include the Optim platform, which allows researchers to measure multiple protein stability parameters simultaneously, and GRUNT, an automated system for biologic formulation preparation. In addition to these, the company provides various tools such as protein sizing systems, stability quantifiers, and automated buffer exchange systems. Unchained Labs serves biopharma and academic customers globally, distributing its products through partnerships in Europe, North and South America, Japan, and other Asian markets.

DNAnexus, Inc. is a provider of cloud-based genome informatics and data management tools aimed at enterprises engaged in genomic medicine. Founded in 2009 and headquartered in Mountain View, California, the company offers a platform that facilitates the analysis of raw sequencing data and integration with clinical and phenotypic data, promoting seamless collaboration among users. Key offerings include MOSAIC Microbiome, a platform for collaborative microbiome research; DNAnexus Apollo, which focuses on clinico-genomic data exploration; and DNAnexus Titan, a comprehensive data analysis solution. Additionally, DNAnexus Portals provide secure online workspaces for cross-disciplinary collaboration. The Clinico-Genomic Data Solution program addresses the need for disease-specific datasets by building networks with healthcare partners to enhance diagnosis and treatment pathways. DNAnexus serves a diverse client base, including biopharmaceutical companies, genome centers, and diagnostic test providers, and has established a strategic alliance with WuXi NextCODE Genomics. The company also maintains additional offices in San Francisco, London, and Prague.

Azura Ophthalmics is a clinical-stage company focused on developing innovative treatments for Meibomian Gland Dysfunction (MGD), a primary cause of dry eye disease (DED). The company's portfolio includes a range of compounds designed to address the underlying causes of MGD and improve health outcomes for individuals suffering from ocular surface diseases, where effective treatment options are limited. Azura utilizes a novel drug delivery platform to enhance the efficacy of its therapies. The company is headquartered in Tel Aviv-Yafo, Israel, with operational presence in Australia and the United States, and is supported by a management team experienced in the development and commercialization of novel ocular treatments.

Engage Therapeutics, based in Summit, New Jersey, is a biopharmaceutical company focused on developing innovative therapies for individuals experiencing uncontrolled epileptic seizures. The company's lead product, Staccato® alprazolam, is a handheld drug-device combination that utilizes an established FDA-approved delivery system to administer alprazolam, an FDA-approved benzodiazepine. This product aims to provide immediate rescue therapy for active seizures, offering a potential solution for patients and their caregivers. In a Phase 2a proof of concept study, Staccato alprazolam demonstrated efficacy in reducing seizures in a photosensitivity model. Engage Therapeutics plans to advance this product into further clinical development through a 505(b)(2) regulatory pathway, positioning it as a promising option for seizure management.

Fusion Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company headquartered in Hamilton, Canada, specializing in the development of radiopharmaceuticals as precision medicines for challenging cancers. The company employs its proprietary Targeted Alpha Therapies platform and Fast-Clear linker technology to connect alpha particle-emitting isotopes to antibodies, enabling the selective delivery of therapeutic agents to tumors. Fusion's lead product candidate, FPI-1434, is currently undergoing Phase 1 clinical trials as a monotherapy for solid tumors expressing insulin-like growth factor 1 receptor. Additionally, the company is exploring the use of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors in preclinical studies to enhance anti-tumor activity. Fusion is also advancing another product candidate, FPI-1966, into clinical development for head and neck and bladder cancers that express fibroblast growth factor receptor. Founded in 2014 as a spinout of the Centre for Probe Development and Commercialization, Fusion aims to transform how cancers are treated through innovative radiochemistry techniques.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, dedicated to developing and commercializing nalbuphine ER, an oral extended-release formulation. The company is focused on treating serious neurologically mediated conditions, specifically chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in individuals with Parkinson's disease. Trevi is currently conducting a Phase 2b/3 clinical trial, known as the PRISM trial, for nalbuphine ER, targeting severe pruritus associated with prurigo nodularis. The conditions being addressed share similar underlying mechanisms that involve opioid receptors in both the central and peripheral nervous systems. Founded in 2011, Trevi Therapeutics aims to provide innovative treatment options for patients suffering from these challenging health issues.

Unchained Labs is a life sciences tools company based in Pleasanton, California, specializing in solutions for biologics and gene therapy researchers. Established in 2014, it develops a range of products designed to enhance the efficiency and effectiveness of research in protein stability and formulation. Key offerings include the Optim platform, which allows researchers to measure multiple protein stability parameters simultaneously, and GRUNT, an automated system for biologic formulation preparation. In addition to these, the company provides various tools such as protein sizing systems, stability quantifiers, and automated buffer exchange systems. Unchained Labs serves biopharma and academic customers globally, distributing its products through partnerships in Europe, North and South America, Japan, and other Asian markets.

Genoa Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of idiopathic pulmonary fibrosis (IPF). It develops GP-101, an aerosol pirfenidone formulation for direct inhalation delivery to the lungs for the treatment of IPF. The company was founded in 2011 and is based in San Diego, California.

Progyny, Inc. is a benefits management company focused on providing comprehensive fertility and family building benefits solutions for employers in the United States. Established in 2008 and headquartered in New York City, Progyny offers a range of services including a differentiated benefits plan design, personalized support through Patient Care Advocates, and access to a selective network of high-quality fertility specialists. The company's fertility benefits solution encompasses treatment services known as Smart Cycles, as well as an integrated pharmacy benefits solution called Progyny Rx, which facilitates access to necessary medications during treatment. Additionally, Progyny addresses the financial aspects of family building by covering surrogacy and adoption expenses for its clients and their employees. Formerly known as Auxogyn, Inc., the company rebranded to Progyny, Inc. in 2015.

Fusion Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company headquartered in Hamilton, Canada, specializing in the development of radiopharmaceuticals as precision medicines for challenging cancers. The company employs its proprietary Targeted Alpha Therapies platform and Fast-Clear linker technology to connect alpha particle-emitting isotopes to antibodies, enabling the selective delivery of therapeutic agents to tumors. Fusion's lead product candidate, FPI-1434, is currently undergoing Phase 1 clinical trials as a monotherapy for solid tumors expressing insulin-like growth factor 1 receptor. Additionally, the company is exploring the use of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors in preclinical studies to enhance anti-tumor activity. Fusion is also advancing another product candidate, FPI-1966, into clinical development for head and neck and bladder cancers that express fibroblast growth factor receptor. Founded in 2014 as a spinout of the Centre for Probe Development and Commercialization, Fusion aims to transform how cancers are treated through innovative radiochemistry techniques.

Adynxx is a biopharmaceutical company established in San Francisco, California, in 2007. It specializes in developing innovative drugs for pain management. The company's primary focus is on creating novel therapeutics called transcription factor decoys to address unmet needs in treating pain and inflammation. Adynxx has two key drug candidates: brivoligide, currently in Phase 2 trials for postoperative pain prevention, and AYX2, a preclinical candidate targeting chronic inflammatory and neuropathic pain syndromes. Additionally, the company offers other therapeutic programs aimed at providing long-term relief for mature chronic pain syndromes.

Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative treatments for migraine. The company's lead product candidate, STS101, is a drug-device combination that features a proprietary dry-powder formulation of dihydroergotamine mesylate. This product is designed for self-administration through a pre-filled, single-use nasal delivery device and is currently undergoing Phase III clinical trials. Founded in 2016 and based in South San Francisco, California, Satsuma aims to provide an effective therapeutic option for individuals suffering from acute migraine episodes.

Avalyn Pharma, Inc. is a biopharmaceutical company focused on developing therapies for idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company is advancing inhaled formulations of pirfenidone, specifically AP01, which aims to enhance drug delivery to the lungs while potentially reducing side effects associated with oral treatments. This innovative approach seeks to improve the care and outcomes for patients suffering from these conditions. Established in 2011, Avalyn Pharma operates from its headquarters in Seattle, Washington, and maintains an additional office in San Diego, California. The company was previously known as Genoa Pharmaceuticals, Inc. before rebranding in July 2017.

Nutrinia Ltd. is a neonatology company focused on developing pharmaceuticals for rare gastrointestinal conditions affecting infants. Established in 2003 and based in Ramat-Gan, Israel, the company is advancing clinical programs, including NTRA-2112, which aims to treat intestinal malabsorption in preterm infants by reducing enteral nutrition intolerance and improving growth metrics, as well as shortening hospital stays. Another significant product in development is NTRA-9620, designed for short bowel syndrome, which promotes bowel adaptation post-surgery and minimizes the need for parenteral nutrition. Nutrinia's offerings primarily consist of oral insulin formulations that facilitate gut adaptation and rehabilitation, thereby enhancing nutritional absorption in infants.

Progyny, Inc. is a benefits management company focused on providing comprehensive fertility and family building benefits solutions for employers in the United States. Established in 2008 and headquartered in New York City, Progyny offers a range of services including a differentiated benefits plan design, personalized support through Patient Care Advocates, and access to a selective network of high-quality fertility specialists. The company's fertility benefits solution encompasses treatment services known as Smart Cycles, as well as an integrated pharmacy benefits solution called Progyny Rx, which facilitates access to necessary medications during treatment. Additionally, Progyny addresses the financial aspects of family building by covering surrogacy and adoption expenses for its clients and their employees. Formerly known as Auxogyn, Inc., the company rebranded to Progyny, Inc. in 2015.

Unchained Labs is a life sciences tools company based in Pleasanton, California, specializing in solutions for biologics and gene therapy researchers. Established in 2014, it develops a range of products designed to enhance the efficiency and effectiveness of research in protein stability and formulation. Key offerings include the Optim platform, which allows researchers to measure multiple protein stability parameters simultaneously, and GRUNT, an automated system for biologic formulation preparation. In addition to these, the company provides various tools such as protein sizing systems, stability quantifiers, and automated buffer exchange systems. Unchained Labs serves biopharma and academic customers globally, distributing its products through partnerships in Europe, North and South America, Japan, and other Asian markets.

Enlibrium is developing novel drugs based on metformin to treat a range of different cancers by reducing cancer energy consumption and reestablishing energy balance. Given their high growth rate and energy requirements, cancers are particularly sensitive to agents that reduce their energy production. Enlibrium was founded based on technology exclusively licensed from UCLA and developed in laboratories headed by Michael Jung, Ph.D. and Richard Pietras, M.D., Ph.D. Enlibrium's investors are Avalon Ventures, TPG Biotech, Correlation Ventures and Osage University Partners.

Rapid Micro Biosystems is a life sciences technology company that specializes in products designed to detect microbial contamination in the manufacturing processes of pharmaceutical, biotechnology, and personal care products. Its flagship offering, the Growth Direct System, automates and modernizes traditional microbial quality control testing, providing a non-destructive method for microbial enumeration. The company, originally established as Genomic Profiling Systems in 2006, rebranded in 2007 and is headquartered in Lowell, Massachusetts, with an additional office in Germany. In addition to its automated systems, Rapid Micro Biosystems offers a range of services, including on-site installation, regulatory compliance assistance, system certification training, and technical support, serving clients across the Americas and Europe. Their solutions are utilized in various applications such as environmental monitoring, water testing, and bioburden testing, facilitating the efficient manufacturing and release of critical healthcare products.

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company dedicated to developing and commercializing products aimed at addressing the challenges associated with pain management and the abuse of prescription drugs. The company utilizes its proprietary DETERx platform technology to create abuse-deterrent formulations that maintain the extended-release and safety profiles of medications, making them less susceptible to misuse through methods such as chewing or injecting. Collegium's primary products include Xtampza ER, an abuse-deterrent extended-release formulation of oxycodone, and Nucynta, which encompasses both extended-release and immediate-release formulations of tapentadol for managing severe pain. Founded in 2002 and headquartered in Stoughton, Massachusetts, Collegium focuses on delivering innovative solutions that enhance patient safety while effectively treating chronic pain conditions.

Unchained Labs is a life sciences tools company based in Pleasanton, California, specializing in solutions for biologics and gene therapy researchers. Established in 2014, it develops a range of products designed to enhance the efficiency and effectiveness of research in protein stability and formulation. Key offerings include the Optim platform, which allows researchers to measure multiple protein stability parameters simultaneously, and GRUNT, an automated system for biologic formulation preparation. In addition to these, the company provides various tools such as protein sizing systems, stability quantifiers, and automated buffer exchange systems. Unchained Labs serves biopharma and academic customers globally, distributing its products through partnerships in Europe, North and South America, Japan, and other Asian markets.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, dedicated to developing and commercializing nalbuphine ER, an oral extended-release formulation. The company is focused on treating serious neurologically mediated conditions, specifically chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in individuals with Parkinson's disease. Trevi is currently conducting a Phase 2b/3 clinical trial, known as the PRISM trial, for nalbuphine ER, targeting severe pruritus associated with prurigo nodularis. The conditions being addressed share similar underlying mechanisms that involve opioid receptors in both the central and peripheral nervous systems. Founded in 2011, Trevi Therapeutics aims to provide innovative treatment options for patients suffering from these challenging health issues.

8990 Holdings, Inc. is a Philippine-based company focused on developing low-cost mass housing projects. It operates through four main segments: Low-Cost Mass Housing, Medium-Rise Condominiums, High-Rise Condominiums, and Others. The company is involved in the development and sale of residential lots and condominium units, along with parking spaces in its condominiums. Additionally, it operates hotels and manages rental properties. Originally incorporated as an information technology and telecommunications provider in 2005, the company rebranded in 2013 to reflect its focus on real estate. Since its restructuring, 8990 Holdings has consolidated various real estate companies to strengthen its market position, with the High-Rise Condominiums segment being the primary revenue generator. The company is headquartered in Makati City, Philippines, where it conducts all its operations.

Otonomy, Inc. is a biopharmaceutical company based in San Diego, California, that specializes in developing therapeutics for ear disorders. The company markets OTIPRIO, a ciprofloxacin otic suspension used during tympanostomy tube placement surgery in pediatric patients. Otonomy is advancing several product candidates, including OTIVIDEX, a sustained-exposure formulation of dexamethasone for Ménière’s disease; OTO-313, a formulation for tinnitus in Phase I/II trials; and OTO-413, aimed at repairing cochlear synaptopathy and addressing speech-in-noise hearing difficulties. Additionally, the company is developing OTO-510, designed to prevent cisplatin-induced hearing loss, and OTO-6XX, which focuses on hair cell regeneration for severe hearing loss. Otonomy employs a proprietary formulation platform that enables sustained drug delivery from a single administration, enhancing treatment options for various ear-related conditions. The company also has strategic collaborations for gene therapy aimed at congenital hearing loss. Founded in 2008, Otonomy continues to lead advancements in otology through innovation and research.

EPIRUS is focusing on the central development of a broad pipeline of biosimilar monoclonal antibodies and therapeutic proteins, optimized for use within the SCALE™ disposable manufacturing system, and designed to be deployed in an "In Market, For Market" ™ manufacturing configuration.

Rapid Micro Biosystems is a life sciences technology company that specializes in products designed to detect microbial contamination in the manufacturing processes of pharmaceutical, biotechnology, and personal care products. Its flagship offering, the Growth Direct System, automates and modernizes traditional microbial quality control testing, providing a non-destructive method for microbial enumeration. The company, originally established as Genomic Profiling Systems in 2006, rebranded in 2007 and is headquartered in Lowell, Massachusetts, with an additional office in Germany. In addition to its automated systems, Rapid Micro Biosystems offers a range of services, including on-site installation, regulatory compliance assistance, system certification training, and technical support, serving clients across the Americas and Europe. Their solutions are utilized in various applications such as environmental monitoring, water testing, and bioburden testing, facilitating the efficient manufacturing and release of critical healthcare products.

DNAnexus, Inc. is a provider of cloud-based genome informatics and data management tools aimed at enterprises engaged in genomic medicine. Founded in 2009 and headquartered in Mountain View, California, the company offers a platform that facilitates the analysis of raw sequencing data and integration with clinical and phenotypic data, promoting seamless collaboration among users. Key offerings include MOSAIC Microbiome, a platform for collaborative microbiome research; DNAnexus Apollo, which focuses on clinico-genomic data exploration; and DNAnexus Titan, a comprehensive data analysis solution. Additionally, DNAnexus Portals provide secure online workspaces for cross-disciplinary collaboration. The Clinico-Genomic Data Solution program addresses the need for disease-specific datasets by building networks with healthcare partners to enhance diagnosis and treatment pathways. DNAnexus serves a diverse client base, including biopharmaceutical companies, genome centers, and diagnostic test providers, and has established a strategic alliance with WuXi NextCODE Genomics. The company also maintains additional offices in San Francisco, London, and Prague.

GoHealth Urgent Care is a healthcare provider that focuses on delivering accessible and high-quality urgent care services. With locations across New York, Oregon, Washington, California, and Connecticut, the company aims to enhance the patient experience through a welcoming environment and efficient service. GoHealth integrates with leading health systems and maintains a broad network of physicians and clinicians, allowing it to offer comprehensive emergency care. The organization is committed to making urgent health services affordable and convenient for patients, with plans for further expansion into new markets.

PatientSafe Solutions, headquartered in San Diego, California, specializes in smart point-of-care mobile solutions aimed at transforming healthcare delivery. Its flagship product, the PatientTouch System, enhances care team productivity and patient safety by consolidating clinical workflows into a single, portable device. The innovative platform integrates communication, workflow management, and real-time access to electronic medical records, facilitating effective collaboration among clinicians. Features such as Positive Patient Identification, customizable care interventions, and real-time alerting capabilities support critical processes like medication administration and specimen collection. By leveraging advanced technology, PatientSafe Solutions enables healthcare providers to improve safety, increase efficiency, and reduce operational costs, positioning itself as a leader in accountable care innovation.

Otonomy, Inc. is a biopharmaceutical company based in San Diego, California, that specializes in developing therapeutics for ear disorders. The company markets OTIPRIO, a ciprofloxacin otic suspension used during tympanostomy tube placement surgery in pediatric patients. Otonomy is advancing several product candidates, including OTIVIDEX, a sustained-exposure formulation of dexamethasone for Ménière’s disease; OTO-313, a formulation for tinnitus in Phase I/II trials; and OTO-413, aimed at repairing cochlear synaptopathy and addressing speech-in-noise hearing difficulties. Additionally, the company is developing OTO-510, designed to prevent cisplatin-induced hearing loss, and OTO-6XX, which focuses on hair cell regeneration for severe hearing loss. Otonomy employs a proprietary formulation platform that enables sustained drug delivery from a single administration, enhancing treatment options for various ear-related conditions. The company also has strategic collaborations for gene therapy aimed at congenital hearing loss. Founded in 2008, Otonomy continues to lead advancements in otology through innovation and research.

Veracyte, Inc. is a genomic diagnostics company based in South San Francisco, California, that specializes in providing advanced diagnostic solutions for cancer and other diseases. Its product offerings include the Afirma Genomic Sequencing Classifier, which helps identify benign thyroid nodules, the Percepta Genomic Sequencing Classifier for lung cancer, and the Envisia Genomic Classifier for distinguishing idiopathic pulmonary fibrosis from other interstitial lung diseases. Additionally, Veracyte offers the Prosigna Breast Cancer Prognostic Gene Signature Assay, which assesses the risk of distant recurrence in breast cancer patients. The company's tests leverage advances in genomic science to reduce the need for invasive procedures, thereby facilitating timely and accurate treatment decisions. Veracyte has established collaborations with Johnson & Johnson Innovation and Loxo Oncology to enhance its diagnostic capabilities and develop targeted therapies for genetically defined cancers. Since its incorporation in 2006 and subsequent name change in 2008, Veracyte has aimed to improve patient care through innovative genomic testing.

Rapid Micro Biosystems is a life sciences technology company that specializes in products designed to detect microbial contamination in the manufacturing processes of pharmaceutical, biotechnology, and personal care products. Its flagship offering, the Growth Direct System, automates and modernizes traditional microbial quality control testing, providing a non-destructive method for microbial enumeration. The company, originally established as Genomic Profiling Systems in 2006, rebranded in 2007 and is headquartered in Lowell, Massachusetts, with an additional office in Germany. In addition to its automated systems, Rapid Micro Biosystems offers a range of services, including on-site installation, regulatory compliance assistance, system certification training, and technical support, serving clients across the Americas and Europe. Their solutions are utilized in various applications such as environmental monitoring, water testing, and bioburden testing, facilitating the efficient manufacturing and release of critical healthcare products.

ChemEOR, Inc. specializes in developing and supplying customized chemical products for the global oil and natural gas production industry. Founded in 2005 and headquartered in Covina, California, the company offers a range of products, including surfactants, polymers, gels, and specialty chemicals. These products are essential for various applications such as well stimulation, reservoir recovery, and flow assurance, particularly in mature fields, shale development, and deep-water operations. ChemEOR employs molecular design techniques to create environmentally friendly and cost-effective formulations, thereby enhancing oil production and recovery rates. The company operates production and distribution facilities in Houston, Los Angeles, Denver, and Midland, facilitating its commitment to improving energy access while minimizing environmental impact.

Alphabet Energy, Inc. specializes in waste heat recovery technology that transforms waste heat into electricity. The company offers a range of products, including power-generating combustors, thermoelectric devices, and both solid-state and liquid-cooled electrical generators, all designed to capture exhaust heat and convert it into usable electrical power. Their innovative products, developed from sustainable materials, can generate power from microwatts to megawatts, catering to diverse industries such as automotive, oil and gas, mining, and manufacturing. Alphabet Energy also provides the PowerModule-β Developer Kit, which allows users to test thermoelectric converters in various applications. Founded in 2009 and headquartered in Hayward, California, with an additional office in Houston, Texas, the company is committed to improving fuel efficiency and reducing energy waste for clients both in the United States and internationally.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, dedicated to developing and commercializing nalbuphine ER, an oral extended-release formulation. The company is focused on treating serious neurologically mediated conditions, specifically chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in individuals with Parkinson's disease. Trevi is currently conducting a Phase 2b/3 clinical trial, known as the PRISM trial, for nalbuphine ER, targeting severe pruritus associated with prurigo nodularis. The conditions being addressed share similar underlying mechanisms that involve opioid receptors in both the central and peripheral nervous systems. Founded in 2011, Trevi Therapeutics aims to provide innovative treatment options for patients suffering from these challenging health issues.

Tandem Diabetes Care, Inc. is a medical device company headquartered in San Diego, California, which specializes in the design, development, and commercialization of insulin delivery systems for individuals with insulin-dependent diabetes. Its flagship product, the t:slim X2 insulin delivery system, includes a pump, a 300-unit disposable insulin cartridge, and an infusion set. The company offers advanced features such as Basal-IQ Technology and Control-IQ Technology, along with the Tandem Device Updater for software enhancements. Additionally, Tandem provides the t:connect web-based data management application and the Sugarmate mobile app to support diabetes management for users and their caregivers. Tandem Diabetes Care entered the insulin pump market in 2012 and has since expanded its product line, including the recent launch of the smaller Mobi pump and development of a tubeless pump. The majority of the company’s revenue is generated in the United States, with additional sales from other developed countries.

Genomatica, Inc. is a biotechnology company based in San Diego, California, specializing in the development of manufacturing processes for intermediate and basic chemicals derived from renewable feedstocks. Founded in 1998, the company utilizes its proprietary biotechnology platform to create fermentation-based processes and to engineer microorganisms that facilitate the conversion of these feedstocks into essential chemicals. Genomatica has successfully commercialized processes for chemicals such as butanediol, which is used in biodegradable plastics and apparel, and butylene glycol, commonly found in cosmetics and personal care products. The company is also actively working on bio-nylon and has developed a pipeline targeting the production of 20 different chemicals. Recognized for its innovative technologies, Genomatica has received numerous accolades, including the Kirkpatrick Award for outstanding chemical engineering technology and the ICIS Innovation Award for its Brontide butylene glycol.

Alder BioPharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapeutic antibodies to improve treatment for migraine patients in the United States, Australia, and Ireland. The company's lead candidate, eptinezumab, is a monoclonal antibody targeting calcitonin gene-related peptide, currently in late-stage clinical development for migraine prevention. Alder is also developing ALD1910, a preclinical monoclonal antibody aimed at inhibiting pituitary adenylate cyclase-activating polypeptide-38 for similar purposes, and Clazakizumab, which targets the pro-inflammatory cytokine interleukin-6 and has completed two Phase 2b trials. In addition to its product development efforts, Alder engages in strategic collaborations, notably with CSL Limited for advancing clazakizumab as a treatment for solid organ transplant rejection. Incorporated in 2002 and headquartered in Bothell, Washington, Alder operates primarily in the United States, where it generates most of its revenue.

Roka Bioscience specializes in the development of rapid and accurate molecular assays and instrument systems aimed at the food safety industry. The company's latest innovation, the Atlas System, introduces advanced molecular rapid pathogen testing, which enhances laboratory efficiency through automation and user-friendly design. By focusing on innovative testing solutions, Roka Bioscience aims to assist food manufacturers in minimizing risks, safeguarding their brands, and addressing the growing demands for testing in the sector.

Founded in 2008, Elevation Pharmaceuticals is developing a pipeline of improved aerosol drug products for COPD patients. There founding team has a successful track record starting companies and building dedicated teams to develop new drug products that improve patients' lives. At Elevation, they have a disciplined approach to strategic decision-making that helps us stay focused on the path with the highest probability of success. They are executing our drug development plans with passion, integrity, and a high sense of urgency in order to meet the needs and expectations of our stakeholders -- employees, investors, partners, and patients.

DNAnexus, Inc. is a provider of cloud-based genome informatics and data management tools aimed at enterprises engaged in genomic medicine. Founded in 2009 and headquartered in Mountain View, California, the company offers a platform that facilitates the analysis of raw sequencing data and integration with clinical and phenotypic data, promoting seamless collaboration among users. Key offerings include MOSAIC Microbiome, a platform for collaborative microbiome research; DNAnexus Apollo, which focuses on clinico-genomic data exploration; and DNAnexus Titan, a comprehensive data analysis solution. Additionally, DNAnexus Portals provide secure online workspaces for cross-disciplinary collaboration. The Clinico-Genomic Data Solution program addresses the need for disease-specific datasets by building networks with healthcare partners to enhance diagnosis and treatment pathways. DNAnexus serves a diverse client base, including biopharmaceutical companies, genome centers, and diagnostic test providers, and has established a strategic alliance with WuXi NextCODE Genomics. The company also maintains additional offices in San Francisco, London, and Prague.

Alphabet Energy, Inc. specializes in waste heat recovery technology that transforms waste heat into electricity. The company offers a range of products, including power-generating combustors, thermoelectric devices, and both solid-state and liquid-cooled electrical generators, all designed to capture exhaust heat and convert it into usable electrical power. Their innovative products, developed from sustainable materials, can generate power from microwatts to megawatts, catering to diverse industries such as automotive, oil and gas, mining, and manufacturing. Alphabet Energy also provides the PowerModule-β Developer Kit, which allows users to test thermoelectric converters in various applications. Founded in 2009 and headquartered in Hayward, California, with an additional office in Houston, Texas, the company is committed to improving fuel efficiency and reducing energy waste for clients both in the United States and internationally.

Roka Bioscience specializes in the development of rapid and accurate molecular assays and instrument systems aimed at the food safety industry. The company's latest innovation, the Atlas System, introduces advanced molecular rapid pathogen testing, which enhances laboratory efficiency through automation and user-friendly design. By focusing on innovative testing solutions, Roka Bioscience aims to assist food manufacturers in minimizing risks, safeguarding their brands, and addressing the growing demands for testing in the sector.

Ultragenyx Pharmaceutical is a biopharmaceutical company based in the United States that specializes in developing therapeutics for rare and ultra-rare diseases, particularly serious genetic disorders. The company focuses on identifying and commercializing innovative treatments that address significant unmet medical needs. Its product portfolio includes Crysvita, which is used to treat X-linked hypophosphatemia, and Mepsevii, indicated for Mucopolysaccharidosis VII. By leveraging existing scientific knowledge and emphasizing clear mechanisms of action, Ultragenyx aims to create impactful therapies for conditions that currently lack effective treatments. The company prioritizes efficient development strategies in a field characterized by limited information and established precedents, drawing on the management team's expertise to advance its mission of improving patient outcomes in rare disease populations.

CardioDx, Inc. is a molecular diagnostics company based in Redwood City, California, focused on developing genomic tests for cardiovascular diseases. Founded in 2003, the company specializes in assessing conditions such as coronary artery disease (CAD), cardiac arrhythmias, and heart failure. One of its key products is the Corus CAD test, a blood test designed to assist healthcare providers in determining whether a non-diabetic patient's chest discomfort or other symptoms are indicative of obstructive CAD. By leveraging genomic technologies, CardioDx aims to deliver critical information that enhances treatment decisions and improves patient outcomes while also addressing the overall cost of care in the United States.

Aerie Pharmaceuticals is a biotechnology company dedicated to the discovery, development, and commercialization of innovative therapies for various eye diseases. Founded in 2005, the company has its headquarters in Bridgewater, New Jersey, and research facilities in Research Triangle Park, North Carolina. Aerie's portfolio includes Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; Rocklatan, a fixed-dose combination of Rhopressa and latanoprost for similar indications; AVX-012, a clinical-stage product candidate for dry eye; and AR-1105 and AR-13503 sustained-release implants for retinal diseases. The company collaborates with DSM on research, development, and licensing agreements.

Elevance Renewable Sciences, Inc. specializes in producing and distributing specialty chemicals derived from natural plant oils through a process known as oil metathesis. Founded in 2007 and headquartered in Woodridge, Illinois, the company develops a diverse range of products, including cleaning ingredients, coating materials, personal care components, and chemical intermediates for various industries such as agriculture, pharmaceuticals, and polymers. Elevance's offerings cater to applications in detergents, coatings, and engineered polymers, among others. In addition to its product lines, the company provides manufacturing consulting, engineering, and technical consulting services focused on bio-based feedstocks and intermediates. By transforming renewable oils into high-performance specialty products, Elevance is positioned to address consumer demand in a growing market.

Otonomy, Inc. is a biopharmaceutical company based in San Diego, California, that specializes in developing therapeutics for ear disorders. The company markets OTIPRIO, a ciprofloxacin otic suspension used during tympanostomy tube placement surgery in pediatric patients. Otonomy is advancing several product candidates, including OTIVIDEX, a sustained-exposure formulation of dexamethasone for Ménière’s disease; OTO-313, a formulation for tinnitus in Phase I/II trials; and OTO-413, aimed at repairing cochlear synaptopathy and addressing speech-in-noise hearing difficulties. Additionally, the company is developing OTO-510, designed to prevent cisplatin-induced hearing loss, and OTO-6XX, which focuses on hair cell regeneration for severe hearing loss. Otonomy employs a proprietary formulation platform that enables sustained drug delivery from a single administration, enhancing treatment options for various ear-related conditions. The company also has strategic collaborations for gene therapy aimed at congenital hearing loss. Founded in 2008, Otonomy continues to lead advancements in otology through innovation and research.

Veracyte, Inc. is a genomic diagnostics company based in South San Francisco, California, that specializes in providing advanced diagnostic solutions for cancer and other diseases. Its product offerings include the Afirma Genomic Sequencing Classifier, which helps identify benign thyroid nodules, the Percepta Genomic Sequencing Classifier for lung cancer, and the Envisia Genomic Classifier for distinguishing idiopathic pulmonary fibrosis from other interstitial lung diseases. Additionally, Veracyte offers the Prosigna Breast Cancer Prognostic Gene Signature Assay, which assesses the risk of distant recurrence in breast cancer patients. The company's tests leverage advances in genomic science to reduce the need for invasive procedures, thereby facilitating timely and accurate treatment decisions. Veracyte has established collaborations with Johnson & Johnson Innovation and Loxo Oncology to enhance its diagnostic capabilities and develop targeted therapies for genetically defined cancers. Since its incorporation in 2006 and subsequent name change in 2008, Veracyte has aimed to improve patient care through innovative genomic testing.

Genomatica, Inc. is a biotechnology company based in San Diego, California, specializing in the development of manufacturing processes for intermediate and basic chemicals derived from renewable feedstocks. Founded in 1998, the company utilizes its proprietary biotechnology platform to create fermentation-based processes and to engineer microorganisms that facilitate the conversion of these feedstocks into essential chemicals. Genomatica has successfully commercialized processes for chemicals such as butanediol, which is used in biodegradable plastics and apparel, and butylene glycol, commonly found in cosmetics and personal care products. The company is also actively working on bio-nylon and has developed a pipeline targeting the production of 20 different chemicals. Recognized for its innovative technologies, Genomatica has received numerous accolades, including the Kirkpatrick Award for outstanding chemical engineering technology and the ICIS Innovation Award for its Brontide butylene glycol.

Tandem Diabetes Care, Inc. is a medical device company headquartered in San Diego, California, which specializes in the design, development, and commercialization of insulin delivery systems for individuals with insulin-dependent diabetes. Its flagship product, the t:slim X2 insulin delivery system, includes a pump, a 300-unit disposable insulin cartridge, and an infusion set. The company offers advanced features such as Basal-IQ Technology and Control-IQ Technology, along with the Tandem Device Updater for software enhancements. Additionally, Tandem provides the t:connect web-based data management application and the Sugarmate mobile app to support diabetes management for users and their caregivers. Tandem Diabetes Care entered the insulin pump market in 2012 and has since expanded its product line, including the recent launch of the smaller Mobi pump and development of a tubeless pump. The majority of the company’s revenue is generated in the United States, with additional sales from other developed countries.

Draths Corporation is a forward-thinking chemical company dedicated to the production of biobased materials for a variety of industries, including chemicals, pharmaceuticals, and food. The company specializes in manufacturing primary chemical ingredients using proprietary technologies that combine metabolic engineering, synthetic biology, and chemical synthesis. Its product offerings include a range of chemicals such as shikimic acid, aminoshikimic acid, quinic acid, butanetriol, phloroglucinol, caprolactam, vanillin, myo-inositol, dehydroshikimic acid, gallic acid, pyrogallol, and tetrahydroxybenzene. Draths' innovative platform technology allows for the creation of materials like nylons, plastics, paints, and resins from renewable feedstocks, significantly reducing carbon footprints while maintaining cost-effectiveness in comparison to traditional petroleum-based processes.

CardioDx, Inc. is a molecular diagnostics company based in Redwood City, California, focused on developing genomic tests for cardiovascular diseases. Founded in 2003, the company specializes in assessing conditions such as coronary artery disease (CAD), cardiac arrhythmias, and heart failure. One of its key products is the Corus CAD test, a blood test designed to assist healthcare providers in determining whether a non-diabetic patient's chest discomfort or other symptoms are indicative of obstructive CAD. By leveraging genomic technologies, CardioDx aims to deliver critical information that enhances treatment decisions and improves patient outcomes while also addressing the overall cost of care in the United States.

ProteoGenix is a company focused on the development and commercialization of diagnostic testing products aimed at the maternal-fetal health sector. Founded in 2002 and headquartered in Costa Mesa, California, with additional offices in Beaverton, Oregon, and Orange County, California, ProteoGenix specializes in non-invasive diagnostic tests. These tests are designed to detect various conditions including intraamniotic infection, neonatal sepsis, preterm birth, preeclampsia, and Down syndrome. The company's efforts are directed towards enhancing maternal-fetal health outcomes through innovative diagnostic solutions.

Tandem Diabetes Care, Inc. is a medical device company headquartered in San Diego, California, which specializes in the design, development, and commercialization of insulin delivery systems for individuals with insulin-dependent diabetes. Its flagship product, the t:slim X2 insulin delivery system, includes a pump, a 300-unit disposable insulin cartridge, and an infusion set. The company offers advanced features such as Basal-IQ Technology and Control-IQ Technology, along with the Tandem Device Updater for software enhancements. Additionally, Tandem provides the t:connect web-based data management application and the Sugarmate mobile app to support diabetes management for users and their caregivers. Tandem Diabetes Care entered the insulin pump market in 2012 and has since expanded its product line, including the recent launch of the smaller Mobi pump and development of a tubeless pump. The majority of the company’s revenue is generated in the United States, with additional sales from other developed countries.

moksha8 Pharmaceuticals, Inc. is a pharmaceutical company that operates in Brazil and Mexico, focusing on the licensing, marketing, and distribution of therapeutics. The company specializes in treatments for various medical fields, including central nervous system disorders, oncology, cardiology, rheumatology, endocrinology, and respiratory conditions. Established in 2006 and based in Berwyn, Pennsylvania, moksha8 has formed strategic alliances with several prominent organizations, including Biopas Laboratories, Roche, Pfizer, BioCryst, and Watson. These partnerships enhance its ability to deliver innovative healthcare solutions in the Latin American market.

JCR Pharmaceuticals is a Japan-based company engaged in the pharmaceutical sector, focusing on the research, production, and sale of medical drugs and pharmaceutical raw materials. The company is particularly active in developing enzymes and proteins to create innovative treatment options for unmet medical needs. In addition to its core pharmaceutical business, JCR Pharmaceuticals also operates in the medical and research equipment market, which includes the purchase and sale of related devices. The company leverages international partnerships as part of its growth strategy, with a significant portion of its revenue generated from pharmaceutical operations, complemented by income from medical devices and licensing agreements.

Alder BioPharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapeutic antibodies to improve treatment for migraine patients in the United States, Australia, and Ireland. The company's lead candidate, eptinezumab, is a monoclonal antibody targeting calcitonin gene-related peptide, currently in late-stage clinical development for migraine prevention. Alder is also developing ALD1910, a preclinical monoclonal antibody aimed at inhibiting pituitary adenylate cyclase-activating polypeptide-38 for similar purposes, and Clazakizumab, which targets the pro-inflammatory cytokine interleukin-6 and has completed two Phase 2b trials. In addition to its product development efforts, Alder engages in strategic collaborations, notably with CSL Limited for advancing clazakizumab as a treatment for solid organ transplant rejection. Incorporated in 2002 and headquartered in Bothell, Washington, Alder operates primarily in the United States, where it generates most of its revenue.

Aerie Pharmaceuticals is a biotechnology company dedicated to the discovery, development, and commercialization of innovative therapies for various eye diseases. Founded in 2005, the company has its headquarters in Bridgewater, New Jersey, and research facilities in Research Triangle Park, North Carolina. Aerie's portfolio includes Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; Rocklatan, a fixed-dose combination of Rhopressa and latanoprost for similar indications; AVX-012, a clinical-stage product candidate for dry eye; and AR-1105 and AR-13503 sustained-release implants for retinal diseases. The company collaborates with DSM on research, development, and licensing agreements.

CardioDx, Inc. is a molecular diagnostics company based in Redwood City, California, focused on developing genomic tests for cardiovascular diseases. Founded in 2003, the company specializes in assessing conditions such as coronary artery disease (CAD), cardiac arrhythmias, and heart failure. One of its key products is the Corus CAD test, a blood test designed to assist healthcare providers in determining whether a non-diabetic patient's chest discomfort or other symptoms are indicative of obstructive CAD. By leveraging genomic technologies, CardioDx aims to deliver critical information that enhances treatment decisions and improves patient outcomes while also addressing the overall cost of care in the United States.